CV Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CV Therapeutics, Inc.
The first COVID-19 vaccine to be approved, Sputnik V, faced production issues soon after, but a solution was found with Sputnik Light. Now, data indicate manufacturing partners in India, China, Korea and other countries could be left holding unsold inventory earmarked for exports as high vaccination numbers will mean limited scope for domestic supplies
Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.